Multiple assay formats have been developed for the pharmacological characterization of G-protein-coupled receptors (GPCRs) and for screening orphan receptors. However, the increased pace of target identification and the rapid expansion of compound libraries present the need to develop novel assay formats capable of screening multiple GPCRs simultaneously. To address this need, the authors have developed a generic dual-reporter gene assay that can detect ligand activity at 2 GPCRs within the same assay. Two stable HEK293 cell lines were generated expressing either a firefly (Photinus) luciferase gene under the control of multiple cAMP-response elements (CREs) or a Renilla luciferase gene under the control of multiple 12-Otetradecanoyl-phorbol-13-acetate (TPA)-responsive elements (TREs). Coseeded reporter cells were used to assess ligandbinding activity at both Gα s -and Gα q -coupled receptors. By selectively coexpressing receptors with a chimeric G-protein, agonist activity was assessed at Gα i/o -coupled receptors in combination with either Gα s -or Gα q -coupled receptors. The dual-reporter gene assay was shown to be capable of simultaneously performing duplexed screens for a variety of agonist and/or antagonist combinations. The data generated from the duplexed reporter assays were pharmacologically relevant, and Z′ factor analysis indicated the suitability of both agonist and antagonist screens for use in high-throughput screening. (Journal of Biomolecular Screening 2005:437-446) 
INTRODUCTION
T HE SUPERFAMILY OF G-PROTEIN-COUPLED RECEPTORS (GPCRs) 1 constitutes the largest known group of transmembrane receptors and is historically the single richest receptor target class for drug discovery. GPCRs have a proven record of being excellent therapeutic targets and are estimated to be the site of action of 50% of marketed drugs. 2 Furthermore, treatment options available for most major therapeutic areas include at least 1 drug that is targeted at a GPCR. 3 The identification and cloning of novel GPCRs has recently expanded rapidly due to the development and application of methods, such as degenerate PCR and low-stringency hybridization, and as a result of advances in bioinformatics, including global assembly of expressed sequence tags and the completion of genome sequencing projects. It is now believed that almost 1000 GPCRs are encoded within the human genome. Although a large proportion of these are olfactory chemosensory receptors, almost 400 are nonsensory and may represent potential therapeutic targets. 4 Approximately 150 nonsensory GPCRs are so-called "orphan" receptors, having no known function or identified endogenous ligand. 5 A diverse array of assays are available for screening GPCRs, the choice of which is of paramount importance when undertaking a ligand identification exercise. A critical issue to address when screening orphan GPCRs is the likely G-protein-coupling specificity of the receptor, which is often unknown. To obviate the need for running multiple assays testing for agonists acting via diverse signaling pathways for a single receptor, generic assays are often employed that ensure a biological response, irrespective of the receptor's endogenous coupling specificity. To date, arguably the most successful assays used to screen GPCRs have involved detecting changes in the intracellular concentration of Ca 2+ in response to agonist activation, with the most widely used protocol involving the coexpression of receptors with promiscuous/chimeric G-proteins and measurement of Ca 2+ mobilization using a Fluorescent Imaging Plate Reader (FLIPR ™ ; Molecular Devices). Reporter gene technology is also widely employed for screening GPCRs as such assays tend to be sensitive, easy to perform, nonradioactive, amenable to automation, low cost, and miniaturizable, and they pro-vide a reliable alternative to traditional second-messenger assays. 6 In addition to measurement of agonist and neutral antagonist activity at heterologously or endogenously expressed GPCRs, 7 the large amplification of signal offered by reporter gene assays allows identification of partial agonist, 8 inverse agonist, 9 and constitutive receptor activity. 10 In recent years, there has been a drive toward the development and implementation of assays that provide increased data content and quality. To achieve this goal, there has been a move toward increasing the number of data points obtained per microplate well by either yielding multiple measurements from a single cell type (i.e., high-content, multiparametric assays) or taking a single measurement from multiple coseeded cell types (i.e., multiplexed assays). 11 Apart from the potential advantages of providing increased information, such assays reduce screening time and reagent expenditure. In addition, multiparametric assays permit the simultaneous assessment of multiple ligand-mediated signaling events within the same assay. Screening strategies combining sensitive reporter gene systems with FLIPR ™ technology have been shown to be amenable to the simultaneous assessment of ligand activity at multiple, unrelated GPCRs and are capable of distinguishing between the activation of distinct Gα s -and Gα q -coupled receptors. 12 Similarly, dual-luciferase reporter assays have previously been described for the application of receptor selectivity studies at multiple Gα s -coupled receptors. 13 In this report, we describe the development of a generic dualluciferase reporter gene assay and demonstrate its use for the simultaneous screening of multiple receptors within the same assay. The assay relies on 2 HEK293-reporter cell lines stably transfected with either a cyclic AMP (cAMP) response element (CRE)-firefly luciferase (CRE-Fluc) or a 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-response element (TRE)-Renilla luciferase (TRE-Rluc) reporter gene construct. By coseeding these reporter cell lines and transiently transfecting both with either a single or a pair of GPCRs, we demonstrate the ability of the luciferase reporter gene assay to simultaneously assess ligand activity at both a Gα i/o -and Gα s -coupled receptor pair and a Gα i/o -and Gα q -coupled receptor pair.
MATERIALS AND METHODS

Materials
Dulbecco's modified eagle medium (DMEM; high glucose) with GlutaMAX ™ , Trypsin-EDTA solution, geneticin (G-418), and MEM nonessential amino acids solution were purchased from Gibco Life Technologies (Paisley, UK). Fetal calf serum (FCS) was purchased from BioWhittaker (Verviers, Belgium). All other chemicals were purchased from Sigma (Poole, UK) and were of the highest purity available.
The Renilla luciferase reporter vector pRL-SV40 was obtained from Promega (Southampton, UK). The cAMP-responsive firefly luciferase plasmid pADneo2-C6-BGL (CRE-Fluc) 14 was a generous gift from Dr. Adolf Himmler (Ernest Boehringer Institute, Vi-enna, Austria). The hamster α1b adrenergic receptor plasmid was kindly provided by Prof. Graeme Milligan (University of Glasgow, UK). The human melanocortin 4 receptor plasmid was a generous gift from Prof. John Findlay (University of Leeds, UK). The human M1 muscarinic acetylcholine receptor plasmid was a kind gift from Dr. Mike Edwardson (University of Cambridge, UK). Human M3 muscarinic acetylcholine receptor plasmid was kindly provided by Dr. Andrew Tobin (University of Leicester, UK). The human D2 (long) dopamine receptor plasmid was obtained from the University of Kent plasmid stocks. The G-protein chimera Gα qo5 plasmid was kindly donated by Dr. Bruce Conklin (Gladstone Institutes, USA).
To generate a TPA-responsive Renilla luciferase reporter vector, a 4-stage construction process was employed. First, a cAMPresponsive Renilla luciferase reporter vector (CRE-Rluc) was constructed by excising the firefly luciferase gene from CRE-Fluc by digestion with HindIII and XbaI and replacing it with Renilla luciferase derived from the plasmid pRL-SV40. Second, oligonucleotides containing multiple copies of a consensus TRE were generated and inserted into the pBluescript II KS+ cloning vector. Third, the cAMP response elements were excised from CRE-Rluc by digestion with NotI and SalI. Finally, the concatenated TREs derived from the pBluescript II KS+ cloning vector were inserted at the CRE-excision point in CRE-Rluc to form TRE-Rluc.
To generate pBluescript II KS+ cloning vectors containing multiple copies of a TRE, a PCR and shotgun cloning approach was taken. A 112-base oligonucleotide (5′-CTAGGA TGAGTCAGGCGGATCCGCATGAGTCAGCCGGCTGCGG GATGAGTCAGGCGACGTCGCATGAGTCAGCCCGCAGC CGGATGAGTCAGGCGGATCCGCATGAGTCAGC-3′), containing 6 copies of a TRE (shown underlined) and 2 BamHI sites (shown in bold), was synthesized. To enrich the desired 112-base product from the crude oligonucleotide mixture, 2 primers 20 bases in length-antisense to the 3′ end of the synthesized oligonucleotide and sense to the 5′ end-were used to amplify the desired oligonucleotide by PCR reaction, using Pwo DNA polymerase (Roche, Lewes, UK). A combination of shotgun cloning and standard cloning techniques was then used to generate a series of cloning vectors containing multiple TRE inserts. The number of inserts and their orientation were confirmed by sequencing (Cytomyx, Cambridge, UK).
Cell culture and transfection
All cell lines were grown in high-glucose DMEM with GlutaMAX ™ containing nonessential amino acids, 10% FCS, but lacking sodium pyruvate. HEK-TRE-Rluc and HEK-CRE-Fluc tested negative for Mycoplasma contamination. Cells were grown at 37°C in a humidified atmosphere containing 5% CO 2 . For transient transfection by electroporation, cells were grown to 80% to 90% confluency in 175-cm 2 culture flasks prior to trypsinization and resuspension in serum-free medium. Resuspension and centrifugation were repeated twice to remove contaminating trypsin and FCS. Cells (1 × 10 7 ) were resuspended in 400 µL of Optimix ® Electroporation Buffer (EquiBio, Kent, UK) and 25 µg of plasmid DNA. The cell/DNA suspension was made up to 800 µL with purified water and placed in a 4-mm electroporation cuvette (EquiBio, Kent, UK). The suspension was pulsed (250 V, 1500 µF, 20 msec) with an EasyjecT PLUS electroporator (EquiBio, Kent, UK) prior to resuspension in complete prewarmed medium. Cells were then seeded in 96-well plates at a density of 4 to 8 × 10 4 cells/well and incubated overnight. The following day, medium was replaced with quiescent medium (serum-and phenol red-free growth medium containing 0.1% w/v bovine serum albumin [BSA]), and the cells were incubated for a further 24 h prior to the functional assay.
For the generation of stable transfectants, cells were grown to 90% confluency in 6-well plates and transfected with 1 µg DNA using Lipofectamine ™ 2000, according to the manufacturer's recommendations. To generate stable cell lines from the transfection, selective medium containing G-418 (0.4 mg/mL) was applied to the cells 48 h after transfection. Cells demonstrating resistance to G-418 were isolated by dilution cloning and screened for inducible luciferase expression in response to standard CRE and TRE activators.
Dual-luciferase reporter gene assay
Cells were seeded into white flat-bottomed 96-well plates at a density of 4 to 8 × 10 4 cells/well in 200 µL growth medium to achieve 90% confluency on the day of the experiment. Ligands were diluted in 60 µL DMEM containing 0.5 mM DTT and applied to the cells following aspiration of overnight growth medium. Cells were then incubated at 37°C with 5% CO 2 for 6 h to allow expression of the reporter gene. Firefly and Renilla luciferase expression was determined using the Dual-Glo ™ Luciferase Assay System (Promega, Southampton, UK), according to the manufacturer's instructions. Luminescence was measured on a MicroBeta ™ Trilux (Wallac, Turku, Finland) for 1 sec/well following a 10-min adaptation to the dark.
Data analysis
Dose-response data generated from reporter gene assays were analyzed using nonlinear regression analysis. Basal expression levels were subtracted, and data were normalized as a percentage of the maximal response (usually obtained with the highest agonist concentration) or, for antagonist assays, as a percentage of the agonist response in the absence of antagonist. Resulting data were fitted to a sigmoidal dose-response curve with variable slope using Graphpad Prism ® (version 2.1). Assay quality was evaluated by determination of the Z′ factor, 15 a statistical characteristic of assay quality that incorporates both the assay's signal dynamic range and the data variation associated with signal measurements.
RESULTS
Optimization of TRE-Renilla reporter constructs
It has been established that varying the number of response element repeats within the promoter region of reporter genes can have a marked effect on reporter gene expression. 14, 16 To identify the optimal number of TREs required for inducing reporter gene expression in response to phorbol ester (TPA) treatment, a collection of TPA-responsive Renilla luciferase (TRE-Rluc) reporter gene vectors was generated containing up to 16 copies of a synthetic consensus TPA-response element. Each of the TRE-Rluc constructs were transfected into HEK293 cells, and reporter gene expression was determined following treatment of the cells with TPA ( Fig. 1 ). In general, an increase in absolute Renilla expression level and signal-to-background ratio was observed with increasing TRE copy number. Highest mean luminescence values and signal amplifications were observed for TRE-Rluc reporter vectors containing either 10 or 16 copies of the consensus TRE. However, the variability of basal expression level and TPA-induced reporter activity was considerably greater for the 16× TRE-Rluc vector compared to the 10× TRE-Rluc vector. Consequently, the 10× TRE-Rluc construct (p10×TRE-Rluc) was adopted as the most suitable vector for generating a stable cell line capable of producing robust, reliable data with low signal variability. 
Development of a Generic Dual-Reporter Gene Assay
Construction and validation of stable HEK-CRE-and HEK-TRE-reporter cell lines
To generate stable HEK-TRE-Rluc clones, HEK293 cells were stably transfected with p10×TRE-Rluc. Transfectants, selected by their resistance to the antibiotic G-418, were clonally isolated by dilution cloning and expanded through several passages. Isolated clones were assayed for reporter gene expression following a 6-h incubation with either 300 nM TPA or vehicle alone (quiescent medium, without serum and phenol red). Several stable HEK-TRE-Rluc clones produced robust induction of reporter expression in response to TPA treatment, showing large amplifications of reporter expression over basal levels.
Similarly, to generate stable HEK-CRE-Fluc clones, HEK293 cells were transfected with the CRE-firefly luciferase reporter gene construct (CRE-Fluc), previously optimized for inducibility in response to activation of the cAMP signaling pathway. 14 Multiple clones were isolated and found to exhibit a strong induction of firefly luciferase activity following a 4-h incubation with 30 µM forskolin (data not shown). A dual-luciferase reporter gene assay was generated by coseeding HEK-TRE-Rluc and HEK-CRE-Fluc reporter cells.
To validate the use of coseeded HEK-TRE-Rluc and HEK-CRE-Fluc for measurement of GPCR activation, the reporter cell lines were mixed in equal number, transiently transfected with a series of well-characterized receptors, and then pharmacologically challenged.
To validate coupling of receptors to cAMP signaling, reporter cells were transfected with the Gα s -coupled human melanocortin 4 (MC4) receptor. 17 Treatment of transfected cells with the nonsubtype-selective melanocortin receptor agonist α-melanocyte stimulating hormone (α-MSH) 18 strongly stimulated CRE-Fluc expression, a response that was readily reversed by coincubating with the potent and selective MC4 receptor antagonist [acetylcys 3 ,Nle 4 ,Arg 5 ,D-2-Nal 7 ,Cys 11 ]-α-melanocyte stimulating hormone fragment 3-11 amide, HS024 19 (Fig. 2) . In contrast, α-MSH failed to induce expression of TRE-Rluc in MC4-transfected cells or expression of either reporter in reporter cells not transfected with the MC4 receptor (data not shown). The pEC 50 for α-MSHstimulated CRE-Fluc expression (8.17 ± 0.09) was similar to that previously found using other CRE-reporter gene and second-messenger assays. 19, 20 Furthermore, the pEC 50 for α-MSH-stimulated CRE-Fluc expression observed using the dual-seeded reporter cells was not significantly different from the value observed with MC4transfected HEK-CRE-Fluc control cells seeded alone (8.29 ± 0.27).
To validate the ability of dual-seeded HEK-CRE-Fluc and HEK-TRE-Rluc to couple reporter gene expression with ligandbinding events occurring at Gα q -coupled receptors, the 2 reporter cell lines were mixed in equal numbers and transfected with the hamster alpha1b adrenergic receptor (α1b-AR), a prototypic Ca 2+mobilizing hormone receptor. 21 Treatment of α1b-transfected cells with the receptor-selective (nonsubtype selective) alpha1 agonist phenylephrine 22 stimulated a dose-dependent increase in TRE-Rluc expression ( Fig. 3 ). The pEC 50 obtained for the phenylephrine-stimulated TRE-reporter expression (6.29 ± 0.04) was similar to that previously found for the α1b-AR, determined using inositol phosphate accumulation studies, 23, 24 and was almost identical to the value observed with α1b expressing HEK-TRE-Rluc control cells seeded alone (6.32 ± 0.09). The present finding that ligand potency is unchanged with coseeded cells versus singly seeded cells agrees with previously published results. 12 Induction of TRE-Rluc expression was not observed following stimulation of untransfected reporter cells with phenylephrine (data not shown), a finding that indicates that the induction of reporter expression in α1b transfected cells was due to the specific stimulation of heterologously expressed α1b receptors.
Interestingly, treatment of α1b expressing reporter cells with phenylephrine also stimulated CRE-Fluc expression (pEC 50 6.51 ± 0.08; Fig. 3 ). In fact, CRE-Fluc expression was much more robust than the concomitant TRE-Rluc response as phenylephrine treatment stimulated firefly luciferase expression approximately 100fold over basal (98.42 ± 4.32), whereas Renilla expression was stimulated less than 4-fold (3.83 ± 1.20). Incubation of phenylephrine-treated reporter cells with the α1-selective antagonist prazosin 22 dose-dependently decreased CRE-Fluc and TRE-Rluc reporter expression to basal levels (pIC 50 = 8.46 ± 0.17), which demonstrates the selective nature of the agonist response in α1b transfected cells.
To further validate the functional coupling of the dual-seeded reporter cell lines to reporter gene expression following ligand binding at Gα q -coupled receptors, the reporter cell lines were coseeded and transfected with either human M1 or M3 muscarinic receptor cDNAs. Treatment of the transfected cells with 10 µM carbachol stimulated significant increases in TRE-Rluc expression (Table 1) . Interestingly, carbachol also stimulated large dose-dependent increases in CRE-Fluc expression. The Z′ factors for the reporter responses from each transfected cell line were found to be above 0.5, with the exception of the TRE-Rluc response for M1 transfected cells. Interestingly, as with the α1b adrenergic transfected reporter cells, more robust responses and larger Z′ factors were obtained with CRE-reporters than with the TRE-reporters, which suggests that CRE-based reporter gene assays may be more suitable than TRE-reporters for assessing Gα q -coupled receptor signaling, albeit through an indirect coupling mechanism.
Application of reporter gene assay to the simultaneous analysis of ligand-binding events at differentially coupled duplexed GPCRs
To demonstrate the ability of the dual-reporter gene assay to measure ligand-binding events at Gα i/o -coupled and Gα s -coupled receptors simultaneously, the 2 reporter cell lines were separately transfected with an appropriately coupled GPCR and coseeded into the same well of a 96-well plate. HEK-CRE-Fluc cells were transfected with the Gα s -coupled MC4 receptor, and HEK-TRE-Rluc cells were cotransfected with the D2 (long) receptor and a chimeric G-protein, Gα qo5 . This chimera consists of Gα q , in which the last 5 C-terminal amino acids have been changed from Gα q to Gα o residues. 25 Analyses of ligand-binding events at Gα i/o -and Gα scoupled receptors were performed simultaneously within the same well of a 96-well microplate (Fig. 4 ). Data generated from the dual-reporter gene assay are displayed in Table 2 . Incubation of coseeded reporter cells with the MC4 agonist α-MSH resulted in a large concentration-dependent increase in CRE-Fluc expression, with a pEC 50 value, signal-to-background ratio, and Z′ factor comparable to those obtained when MC4 agonist activity was assessed alone (Fig. 2) . Incubation of the coseeded cells with the D2 agonist, N-n-propylnorapomorphine (NPA), generated a pEC 50 (6.48 ± 0.07) that closely agrees with a previously published cAMP accumulation study conducted on endogenously expressed D2 receptors in isolated human trophoblastic cells. 26 However, this value is several orders of magnitude higher than the IC 50 stated in other reports describing NPA-mediated stimulation of D2 receptors in Sf21 (8.75 ± 0.22 nM) 27 and Chinese hamster ovary (CHO) cell lines (9.94 ± 0.06 nM). 28 This discrepancy may be accounted for by the loss or gain of high-affinity ligand-binding sites that is observed following interaction of the D2 (long) receptor with different adenylyl cyclase-inhibiting G-protein subtypes. 27 Thus, it is possible that coexpression of the receptor with a chimeric G-protein alters the nature of the receptor's pharmacological profile. Indeed, Gα i -coupled receptors that are forced to signal through PLCβ via a chimeric G-protein often display reduced potency for agonists. 29 In addition, differences in reported IC 50 values may reflect different levels of receptor expression in the various cellular systems used and may also partly reflect the use of different functional assays to assess receptor efficacy. 30, 31 Importantly, agonist responses in the dual-reporter gene assay generated Z′ factors of above 0.5 (Table  2) , which indicates that the dual assay is suitable for simultaneously determining agonist activity at Gα i/o -and Gα s -coupled receptors in a high-throughput screening (HTS) environment.
The suitability of the dual-reporter gene assay for the simultaneous determination of antagonist efficacy at Gα s -and Gα i/o - Cells were transiently transfected with the alpha1b adrenergic receptor (α1b-AR) and then incubated with increasing concentrations of phenylephrine alone or with phenylephrine at 10 µM, as well as increasing concentrations of prazosin for 6 h at 37°C in a humidified atmosphere containing 5% CO 2 in air, and then both firefly and Renilla luciferase activity was measured. Results are the mean ± SEM of 3 independent transfection experiments performed in triplicate, normalized to the highest phenylephrine response observed. coupled receptors was also investigated. Coincubation of the reporter cells with the selective D2 antagonist, remoxipride, and the MC4 antagonist, HS024, resulted in dose-dependent inhibitions of NPA-and α-MSH-stimulated reporter expression (Fig. 4) . The pIC 50 value for the MC4 antagonist response was very similar to the value obtained when MC4 agonism and antagonism were tested alone (Fig. 2) . These data indicate that coassessment of duplexed receptors using the dual-reporter gene assay is sufficiently sensitive to permit the simultaneous analysis of dual-antagonist responses without altering the pharmacological potency of the ligand-evoked receptor response.
Development of a Generic Dual-Reporter Gene Assay
To demonstrate the ability of the dual-reporter gene assay to simultaneously analyze ligand-binding events at Gα i/o -and Gα qcoupled receptors, the 2 HEK-reporter cell lines were separately transfected with either a Gα i/o -or Gα q -coupled receptor and coseeded into the same well of a 96-well plate. To generate a sensitive assay system for coscreening Gα q -and Gα i/o -coupled receptors, HEK-CRE-Fluc cells were transfected with the Gα qcoupled α1b-AR, and HEK-TRE-Rluc cells were cotransfected with the D2 (long) dopamine receptor and Gα qo5 . Following costimulation of the heterologously expressed Gα i/o -and Gα q -coupled receptors with the subtype-specific D2 agonist NPA and the α1-AR specific agonist phenylephrine, a marked increase in both firefly and Renilla luciferase expression was observed ( Fig. 5 ). When coassessed within the same assay, the Z′ factor for each agonist assay was found to be over 0.5 ( Table 3) , indicating that the dual-reporter gene assay can be used to coassess agonist activity at both Gα i/o -and Gα q -coupled receptors.
In addition to measuring simultaneously duplexed agonist binding, the dual-reporter gene assay was used to combine an agonist assay and an independent antagonist assay ( Fig. 6 ). HEK-CRE-Fluc cells transfected with α1b-AR were coseeded with HEK-TRE-Rluc cells that had been cotransfected with the D2 (long) receptor and Gα qo5 . Treatment with phenylephrine generated a concentration-dependent increase in CRE-Fluc expression (pEC 50 = 6.32 ± 0.10). The reporter cells were also coincubated with 1 µM NPA and increasing concentrations of remoxipride. A dosedependent decrease in NPA-induced TRE-Rluc expression was observed, with a pIC 50 of 5.75 ± 0.09 (Fig. 6 ). Z′ factor analyses indicate that the dual-reporter gene assay is also acceptable for simultaneous measurement of agonist and antagonist activity at duplexed GPCRs in an HTS format ( Table 3) .
DISCUSSION
A collection of reporter gene vectors was generated, each containing response elements sensitive to signaling via either the adenylyl cyclase/cAMP or phospholipase C/diacyl-glycerol (DAG)/phorbol ester signaling pathways. The CRE-Fluc and TRE-Rluc reporters were generated on separate reporter plasmids and were subsequently used to generate 2 distinct HEK-reporter cell lines. The reporter constructs were not generated on a single bi-cistronic vector or routinely cotransfected into the same cell line because the CRE and TRE are composed of highly similar consensus sequences. Consequently, such an approach is likely to have impaired the ability of the luciferase-coupled response elements to faithfully report upstream signaling events due to competition be- Cells were incubated with ligands for 6 h at 37°C in a humidified atmosphere containing 5% CO 2 in air, and then both firefly and Renilla luciferase activity was measured. pEC 50 /pIC 50 values were estimated by fitting sigmoidal dose-response curves (Graphpad Prism ® ) with variable slope to the data. Results are the mean ± SEM of 3 independent transfection experiments performed in triplicate. α-MSH, α-melanocyte stimulating hormone; NPA, N-n-propylnorapomorphine. Reporter cells were incubated with increasing concentrations of both α-melanocyte stimulating hormone (α-MSH) and N-n-propylnorapomorphine (NPA) simultaneously, or with 0.1 µM α-MSH and 1 µM NPA, and increasing concentrations of the antagonists, HS024 and remoxipride, for 6 h at 37°C in a humidified atmosphere containing 5% CO 2 in air, and then both firefly and Renilla luciferase activity was measured. Values are expressed as a percentage of the maximal luciferase induction observed following agonist stimulation alone (i.e., α-MSH or NPA, usually achieved with the highest concentration tested) or following agonist stimulation in the absence of antagonist (i.e., for α-MSH at 10 -7 M and for NPA at 10 -6 M) for the respective reporters. Results are the mean ± SEM of 3 independent transfection experiments performed in triplicate. Agonist and antagonist assays were performed separately. tween CRE and AP-1 binding proteins. Indeed, competition for transcriptional coactivators has been shown to alter the transcriptional properties of the CRE and TRE elements located in the 5′-flanking region of the 5-aminoevulinate synthase gene. 32 As well as reducing transcriptional cross talk, the generation of reporter constructs on separate plasmids in 2 distinct cell lines allows them to be used in isolation once the receptor coupling mechanism has been identified, thereby reducing possible background reporter activity.
To validate the use of the dual-luciferase reporter assay as a tool for assessing ligand activity at GPCRs, the HEK-reporter cell lines were transiently transfected with a range of well-characterized receptors coupled via diverse G-protein mechanisms. It was found that activation of heterologously expressed Gα q -coupled receptors stimulated the activity of both CRE-Fluc and TRE-Rluc reporters, whereas Gα s -coupled receptors only activated CRE-Fluc reporter activity. Therefore, the coseeded dual-reporter gene assay may potentially provide a simple means to assess receptor coupling. It is interesting to note that several other groups have also shown signaling of recombinantly expressed Gα q -coupled receptors via CREs when the receptors are expressed in HEK293 cells. This phenomenon has been shown to occur following the stimulation of both peptide 33 and prostanoid receptors, 34 which suggests that the dual signaling is not limited to Gα q -coupled biogenic amine receptors, as described here, but may be common to all Gα q -coupled members of the family A GPCRs. Alternatively, it may be a signaling mechanism common to all Gα q -coupled GPCRs recombinantly expressed in HEK293 cells. Indeed, the data presented here suggest that CRE-coupled reporters may be more robust than TREcoupled reporters for the determination of Gα q -coupled receptor signaling when receptors are recombinantly expressed in HEK293 cells.
The ability of the dual-reporter assay to indicate ligand binding at 2 GPCRs simultaneously was demonstrated by coscreening Gα i/o -coupled receptors with either Gα q -or Gα s -coupled receptors . Because measurement of Gα i/o activation (as a reduction of CRE-luciferase expression) normally requires pretreatment with the adenylate cyclase activator, forskolin, and Gα i/o activation inhibits the elevation in cAMP induced by Gαs activation, this was achieved by coexpressing the Gα i/o -coupled receptor with the chimeric Gα qo5 , allowing Gα i/o -coupled receptor activity to be measured via TRE-Rluc expression. Gα s -coupled receptor activity was measured conventionally via CRE-Fluc expression, whereas Gα qcoupled receptor activity was also measured by this reporter via signaling cross talk. In contrast to conventional CRE-based reporter gene assays for Gα i/o -coupled GPCRs that produce a reduction in reporter expression, use of chimeric or promiscuous G-proteins permits agonist activity to be read as a positive readout and thereby reduces the number of false positives generated from Gα i/o -coupled agonist screens. The data generated from the duplexed reporter assays described here were pharmacologically relevant and consistent with data derived from traditional second-messenger assays described in the literature. As well as successfully coassessing duplexed agonist responses, the dual-reporter assay proved to be sufficiently robust to perform duplexed antagonist assays or duplexed agonist and antagonist assays simultaneously. Moreover, Z′ factor analysis of duplexed agonist and antagonist assays confirmed the robustness of these assays for HTS and demonstrated that duplexing does not compromise data quality.
In addition to providing a sensitive assay for the identification of receptor ligands, dual-reporter gene systems may also provide a convenient means for investigating the extent of cross talk occurring between different signaling pathways. By using the same methodology to measure the activity of different signaling pathways, dual-reporter gene assays avoid the inherent problems associated with making comparisons between different assays using different methods of signal detection. 29 By coassessing the activity of a second reporter that is coupled to an alternative major signaling pathway, important information regarding the selectivity of an inhibitor for individual signaling pathways may be obtained. Furthermore, in many situations, a pathway-specific reporter gene may be able to act as an internal control to confirm the absence of cytotoxic effects associated with a particular experimental condition.
Dual-reporter gene assays may also have other applications. In recent years, evidence has been provided to support the notion that all agonists acting at a specific GPCR do not produce the same active state. Rather, the activation of GPCRs may involve ligandspecific enrichment of multiple active receptor conformations that are capable of differentially regulating distinct effectors. Such direction of receptor-mediated signals into various signaling pathways through alternate receptor confirmations is termed stimulus trafficking. 35 One approach to the detection of agonist-selective receptor conformations would be to monitor receptor/G-protein coupling following receptor activation with multiple agonists. The best evidence for stimulus trafficking is obtained when agonists stimulate distinct pathways via a common receptor with differential agonist potency. By providing a sensitive, simple method for monitoring 2 signal transduction pathways within the same assay, the dual-reporter assay may provide a useful method by which agonist-selective receptor active states may be identified, thus enabling the identification of ligands with reduced side effects. Potentially, dual-reporter gene assays may provide insights into preferred profiles of agonism as compounds are progressed from screening assays into therapeutically oriented secondary assays. 35 The dual-luciferase reporter gene assay has been shown to be a highly versatile, generic assay that can be used to perform multiple agonist and/or antagonist screens simultaneously. In this study, 2 stably transfected reporter cell lines, HEK-CRE-Fluc and HEK-TRE-Rluc, were generated that may be used to coscreen 2 Gα scoupled receptors, 2 Gα q -coupled receptors, 2 Gα i/o -coupled receptors, or a Gα i/o -coupled receptor with either a Gα s -or Gα qcoupled receptor. By generating a third HEK-reporter cell line stably transfected with CRE-Rluc, it would be possible to simultaneously coscreen 2 Gs-coupled receptors 13 and thus any combination of 2 GPCRs, whether Gα s , Gα i/o , or Gα q coupled. Furthermore, by multiplexing the HEK-reporter cells with other reporter cell lines, it may be possible to increase the number of receptors that may be screened concurrently. For example, the inclusion of green fluorescent protein (GFP)-based reporters, coupled to either CREs or TREs, could allow 3 or more receptors to be coscreened. However, the inclusion of a third reporter with a fluorescent readout would complicate the assay protocol and may limit the ease with which the assay could be integrated into an HTS platform.
Although the dual-luciferase reporter assay described here was performed in a 96-well plate format, luciferase-based reporter assays are widely used in smaller formats, such as 384-well plates, and can be sensitive enough to be performed in an ultra-highthroughput format (e.g., 1536). 36 However, it should be emphasized that the assay described here has not been tested in either a 384-well or smaller format.
In summary, we have shown the dual-reporter gene assay to be a highly versatile assay, possessing many unique characteristics that enable it to be a useful tool for both pharmaceutical and academic research. The dual-reporter gene assay may be of use in performing duplexed primary screens or for combining primary and secondary selectivity screens. It may be used to determine the coupling specificity of poorly characterized receptors, analyze signaling cross talk, or help to elucidate the biochemical mechanisms of receptor-mediated signaling pathways. It should therefore become a basic tool in the cell biology, pharmacology, and drug discovery toolbox.
